ADDITIONAL INFORMATION CONTINUED EMPLOYEE REMUNERATION The number of employees, not being directors of the Company, who received remuneration and benefits in their capacity as employees totalling NZ $100,000 or more during the year, shown in bands denominated in Australian dollars, was as follows: Excluding share based payments 2024 $’000 2023 $’000 $120,000 – $129,999 1 – $150,000 – $159,999 1 – $180,000 – $189,999 1 – $190,000 – $199,999 – 1 $200,000 – $209,999 – 1 $210,000 – $219,999 1 – $220,000 – $229,999 – 1 $250,000 – $259,999 1 – $260,000 – $269,999 1 – $280,000 – $289,999 – 1 $290,000 – $299,999 1 – $300,000 – $309,999 – 1 $320,000 – $329,999 1 – $330,000 – $339,999 1 – $480,000 – $489,999 – 1 $510,000 – $519,999 – 1 $640,000 – $649,999 – 1 Including share based payments 2024 $’000 2023 $’000 $120,000 – $129,999 1 – $180,000 – $189,999 1 – $190,000 – $199,999 – 1 $200,000 – $209,999 – 1 $220,000 – $229,999 – 1 $270,000 – $279,999 1 – $280,000 – $289,999 1 – $300,000 – $309,999 1 – $340,000 – $349,999 1 – $360,000 – $369,999 1 – $390,000 – $399,999 – – $480,000 – $489,999 1 – $510,000 – $519,999 – 1 $590,000 – $599,999 – 1 $630,000 – $639,999 – 1 $650,000 – $659,999 – 1 $660,000 – $669,999 1 – $1,200,000 – $1,209,999 – 1 Neuren Pharmaceuticals Limited Annual Report 2024 53
RkJQdWJsaXNoZXIy MjE2NDg3